Literature DB >> 19211844

Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis.

Petra Obexer1, Judith Hagenbuchner, Thomas Unterkircher, Nora Sachsenmaier, Christoph Seifarth, Günther Böck, Verena Porto, Kathrin Geiger, Michael Ausserlechner.   

Abstract

The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB) pathway regulates survival and chemotherapy resistance of neuronal cells, and its deregulation in neuroblastoma (NB) tumors predicts an adverse clinical outcome. Here, we show that inhibition of PI3K-PKB signaling in human NB cells induces nuclear translocation of FOXO3/FKHRL1, represses the prosurvival protein BIRC5/Survivin, and sensitizes to DNA-damaging agents. To specifically address whether FKHRL1 contributes to Survivin regulation, we introduced a 4-hydroxy-tamoxifen-regulated FKHRL1(A3)ERtm allele into NB cells. Conditional FKHRL1 activation repressed Survivin transcription and protein expression. Transgenic Survivin exerted a significant antiapoptotic effect and prevented the accumulation of Bim and Bax at mitochondria, the loss of mitochondrial membrane potential as well as the release of cytochrome c during FKHRL1-induced apoptosis. In concordance, Survivin knockdown by retroviral short hairpin RNA technology accelerated FKHRL1-induced apoptosis. Low-dose activation of FKHRL1 sensitized to the DNA-damaging agents doxorubicin and etoposide, whereas the overexpression of Survivin diminished FKHRL1 sensitization to these drugs. These results suggest that repression of Survivin by FKHRL1 facilitates FKHRL1-induced apoptosis and sensitizes to cell death induced by DNA-damaging agents, which supports the central role of PI3K-PKB-FKHRL1 signaling in drug resistance of human NB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211844      PMCID: PMC2663932          DOI: 10.1091/mbc.e08-07-0699

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  25 in total

1.  Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways.

Authors:  S L Shankar; S Mani; K N O'Guin; E R Kandimalla; S Agrawal; B Shafit-Zagardo
Journal:  J Neurochem       Date:  2001-10       Impact factor: 5.372

2.  An IAP-IAP complex inhibits apoptosis.

Authors:  Takehiko Dohi; Kazuya Okada; Fang Xia; Casey E Wilford; Temesgen Samuel; Kate Welsh; Hiroyouki Marusawa; Hua Zou; Robert Armstrong; Shu-ichi Matsuzawa; Guy S Salvesen; John C Reed; Dario C Altieri
Journal:  J Biol Chem       Date:  2004-06-24       Impact factor: 5.157

3.  FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling.

Authors:  Wen-Hua Zheng; Satyabrata Kar; Rémi Quirion
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

4.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.

Authors:  A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

5.  Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells.

Authors:  M J Ausserlechner; P Obexer; G Böck; S Geley; R Kofler
Journal:  Cell Death Differ       Date:  2004-02       Impact factor: 15.828

6.  Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells.

Authors:  Tong Liu; Brook Brouha; Douglas Grossman
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

7.  Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.

Authors:  Sunghoon Kim; Junghee Kang; Jingbo Qiao; Robert P Thomas; B Mark Evers; Dai H Chung
Journal:  J Pediatr Surg       Date:  2004-04       Impact factor: 2.545

8.  Regulation of mitochondrial Smac/DIABLO-selective release by survivin.

Authors:  G Ceballos-Cancino; M Espinosa; V Maldonado; J Melendez-Zajgla
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

9.  FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity.

Authors:  Pascale F Dijkers; Kim U Birkenkamp; Eric W-F Lam; N Shaun B Thomas; Jan-Willem J Lammers; Leo Koenderman; Paul J Coffer
Journal:  J Cell Biol       Date:  2002-01-28       Impact factor: 10.539

10.  FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons.

Authors:  Jonathan Gilley; Paul J Coffer; Jonathan Ham
Journal:  J Cell Biol       Date:  2003-08-11       Impact factor: 10.539

View more
  32 in total

1.  Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.

Authors:  Xin Liu; Lindsay Ryland; Jun Yang; Aijun Liao; Cesar Aliaga; Rebecca Watts; Su-Fern Tan; James Kaiser; Sriram S Shanmugavelandy; Andrew Rogers; Kathleen Loughran; Bailey Petersen; Jonathan Yuen; Fanxue Meng; Kendall Thomas Baab; Nancy Ruth Jarbadan; Kathleen Broeg; Ranran Zhang; Jason Liao; Thomas Joseph Sayers; Mark Kester; Thomas P Loughran
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

2.  BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

Authors:  J Hagenbuchner; U Kiechl-Kohlendorfer; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

3.  Mitochondrial survivin - an Achilles' heel in cancer chemoresistance.

Authors:  Michael J Ausserlechner; Judith Hagenbuchner
Journal:  Mol Cell Oncol       Date:  2015-07-29

4.  Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Authors:  Regina Berger; Heidi Fiegl; Georg Goebel; Petra Obexer; Michael Ausserlechner; Wolfgang Doppler; Cornelia Hauser-Kronberger; Roland Reitsamer; Daniel Egle; Daniel Reimer; Elisabeth Müller-Holzner; Allison Jones; Martin Widschwendter
Journal:  Cancer Sci       Date:  2010-01-12       Impact factor: 6.716

Review 5.  Survivin as a global target of intrinsic tumor suppression networks.

Authors:  Minakshi Guha; Dario C Altieri
Journal:  Cell Cycle       Date:  2009-09-07       Impact factor: 4.534

6.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

Authors:  Anindita Chakrabarty; Neil E Bhola; Cammie Sutton; Ritwik Ghosh; María Gabriela Kuba; Bhuvanesh Dave; Jenny C Chang; Carlos L Arteaga
Journal:  Cancer Res       Date:  2012-11-29       Impact factor: 12.701

7.  Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.

Authors:  Don Eslin; Chris Lee; Umesh T Sankpal; Pius Maliakal; Robert M Sutphin; Liz Abraham; Riyaz Basha
Journal:  Tumour Biol       Date:  2013-05-18

8.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01

9.  Anti-leukemic response of a NSAID, tolfenamic acid.

Authors:  Robert M Sutphin; Sarah F Connelly; Chris M Lee; Umesh T Sankpal; Don Eslin; Moeez Khan; Hima Pius; Riyaz Basha
Journal:  Target Oncol       Date:  2013-04-23       Impact factor: 4.493

Review 10.  Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer.

Authors:  Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.